Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
SAN FRANCISCO and SUZHOU, China, July 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent Biologics' Artificial Intelligence for Drug Discovery platform . Through this collaboration, both parties will combine their respective strengths and technologies to further accelerate the drug discovery and development process using AI technology.
因塞特生物醫藥(Innovent)(香港交易所:01801)是一家世界一流的生物製藥公司,致力於開發、製造和商業化用於治療腫瘤、心血管和代謝性疾病、自身免疫性疾病、眼科醫療以及其他重大疾病的高質量藥物。今天宣佈與WeComput達成戰略合作伙伴關係,共同推進因塞特生物製品的藥物發現平台的建設和改進人工智能。通過這一合作,雙方將結合各自的優勢和技術,進一步加速使用人工智能技術的藥物發現和開發過程。
As an important R&D engine of Innovent, Innovent Academy has been deeply exploring and actively deploying AI drug research and development. In this collaboration, Innovent Academy will utilize WeComput's WeMol, a molecular design platform, to build and enhance its computing infrastructure, accelerating the drug research and development process. Meanwhile, WeMol will integrate NVIDIA's BioNeMo to further expand the computing capability of Innovent's AI systems and improve computational efficiency.
因諾維學院作爲因塞特的一種重要的研發引擎,一直在深入探索和積極部署人工智能藥物研究和開發。在這項合作中,因諾維學院將利用WeComput的分子設計平台WeMol來構建和增強其計算基礎設施,加速藥物研究和開發過程,同時,WeMol將集成英偉達的BioNeMo來進一步擴大因塞特的AI系統的計算能力,提高計算效率。
Innovent and WeMol will integrate their technological strengths to create a comprehensive AI-driven drug discovery and development system that is efficient, user-friendly, digitalized, intelligent and automated. This cooperation will allow Innovent to significantly reduce AI implementation and experimental costs, shorten the drug R&D cycle, improve R&D success rate, and deliver more innovative drugs and treatment options to patients.
因塞特和WeMol將整合各自的技術優勢,創建一個全面的基於人工智能的藥物發現和開發系統,高效、用戶友好、數字化、智能和自動化。這種合作將使因塞特大幅降低人工智能實施數和實驗成本,縮短藥物研發週期,提高研發成功率,爲患者提供更多創新藥物和治療選擇。
Dr. Kaijie He, Vice President of Oncology Biology and ADC Drug Research, said, "AI is injecting new momentum into the global pharmaceutical and biotech industries. We are excited to partner with WeComput and integrate advanced AI technology to boost our R&D capabilities and expedite the discovery and development of innovative drugs. We believe this collaboration will offer robust technical support to our research team, propelling us toward greater breakthroughs in the global pharmaceutical market."
腫瘤生物學與ADC藥物研究副總裁何凱傑博士表示:“人工智能正在爲全球製藥和生物技術行業注入新的動力。我們很高興能與WeComput合作,整合先進的人工智能技術,提升我們的研發能力,加速創新藥物的發現和開發。我們相信,這種合作將爲我們的研究團隊提供強有力的技術支持,並推動我們在全球製藥市場上取得更大的突破。”
Harry (Hu) Ge, CEO of WeComput, stated, "This collaboration will be mutually beneficial, fostering the widespread application of AI technology in the biopharmaceutical sector and driving innovation and development in the global pharmaceutical industry."
WeComput的首席執行官Harry(胡)Ge表示:“這種合作將是互惠互利的,促進人工智能技術在生物製藥領域的廣泛應用,並推動全球製藥產業的創新和發展。”
About Innovent Biologics
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 10 products in the market. It has 4 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.
關於因塞特生物醫藥
因塞特是一家領先的生物製藥公司,成立於2011年,其使命是爲全球患者提供價格實惠、高質量的生物製藥。該公司發現、開發、製造和商業化針對一些頑疾的創新藥物,包括腫瘤、心血管和代謝性疾病、自身免疫性疾病和眼科疾病。因塞特已經在市場上推出了10款產品。其有4個新藥申請正在接受監管審查,有4個資產處於III期或關鍵臨床試驗階段,還有18種化合物處於早期臨床階段。因塞特與全球30多家醫療保健企業合作,包括禮來、賽諾菲、因塞特、Adimab、LG Chem和MD Anderson癌症中心。
Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn.
康德新的座右銘是“始於誠信,成功於行動”,保持着業界最高的行業標準,致力於推動生物製藥行業的發展,使一流的製藥產品成爲廣泛可及的。有關更多信息,請訪問或在Facebook和LinkedIn上關注康德新。
About WeComput
WeComput is dedicated to "computational technology driving innovative drug research and development." With a profound understanding of the innovative drug development process, WeComput integrates artificial intelligence, biophysics, and high-performance computing technologies to create a unique digital, intelligent and automated platform for drug molecule generation, design and simulation. This platform is poised to revolutionize traditional drug discovery methods and drive the research and development of innovative drugs such as antibodies, proteins, small molecules and mRNA. The parent company, Beijing Zhongda Weixin Technology Co., Ltd., was registered in 2015 and has been recognized as a national high-tech enterprise. In 2021, it received equity investment from Sequoia Capital and was selected as a senior member of the NVIDIA Inception program. To date, WeComput has served hundreds of clients worldwide, including numerous biopharmaceutical companies, universities, hospitals, and research institutions, and has independently developed the leading drug molecule design and intelligent computing platform, WeMol.
關於WeComput
WeComput致力於“計算技術推動創新藥物研究和開發”。WeComput憑藉對創新藥物開發過程的深刻理解,整合了人工智能、生物物理學和高性能計算技術,創建了一個獨特的數字化、智能和自動化平台,用於藥物分子的生成、設計和模擬。該平台有望徹底改變傳統的藥物發現方法,並推動抗體、蛋白質、小分子和mRNA等創新藥物的研究和開發。母公司北京中大微信科技有限公司成立於2015年,並獲得國家高新技術企業認定。2021年,它獲得了紅杉資本的股權投資,並被選爲英偉達創業計劃的高級成員。截至目前,WeComput已爲全球數百個客戶提供服務,包括許多生物製藥公司、高校、醫院和研究機構,並獨立開發了領先的藥物分子設計和智能計算平台WeMol。
SOURCE Innovent Biologics
來源於康泰生物製品